Johnson & Johnson (JNJ)
Johnson & Johnson on one page: short interest, daily short volume, fails to deliver, planned sales, large holders, 13F holders, financials, federal contracts, earnings dates and insider trades. Listed on NYSE, classified by the SEC as pharmaceutical preparations.
16.8M
Short interest
settlement 2026-10-15
2.0
Days to cover
-1.3 days vs prior
29.8%
Short share of volume
2026-10-28
129
Fails to deliver
settlement 2026-09-30
Wed 20 Jan
Next earnings
estimated date
-$62.0M
Insider flow, 90 days
0 buys, 9 sells
As of 2026-10-28.
Short interest
FINRA, twice a month. The newest 48 settlements in the table, 48 in the chart. JSONAs of 15 October 2026, short interest in JNJ is 16,766,729 shares, down 4,421,793 shares over the last month. Over the last 48 readings it ranged from 15,824,423 shares (30 June 2025) to 27,425,456 shares (15 July 2026). The latest reading sits at the bottom of that range. At the reported average volume of 8.5M shares a day that is 2.0 days to cover.
Embed this chart.The embed keeps its attribution line.
<iframe src="https://xoomar.com/embed/stocks/jnj" width="100%" height="440" style="border:0;max-width:100%" loading="lazy" title="XOOMAR chart"></iframe>
| Settlement | Shares short | Change | Avg daily volume | Days to cover |
|---|---|---|---|---|
| 2026-10-15 | 16,766,729 | -24.0% | 8,521,244 | 1.97 |
| 2026-09-30 | 22,070,973 | +4.2% | 6,751,004 | 3.27 |
| 2026-09-15 | 21,188,522 | -2.2% | 5,808,653 | 3.65 |
| 2026-08-31 | 21,670,595 | +0.4% | 6,551,728 | 3.31 |
| 2026-08-14 | 21,591,738 | -15.0% | 6,484,655 | 3.33 |
| 2026-07-31 | 25,408,119 | -7.4% | 8,495,614 | 2.99 |
| 2026-07-15 | 27,425,456 | +3.2% | 7,473,091 | 3.67 |
| 2026-06-30 | 26,576,975 | -0.4% | 10,724,470 | 2.48 |
| 2026-06-15 | 26,689,694 | +14.0% | 7,398,392 | 3.61 |
| 2026-05-29 | 23,407,721 | +1.6% | 7,937,059 | 2.95 |
| 2026-05-15 | 23,038,990 | +3.1% | 7,536,326 | 3.06 |
| 2026-04-30 | 22,349,005 | +13.6% | 8,143,760 | 2.74 |
| 2026-04-15 | 19,671,868 | -11.7% | 7,066,481 | 2.78 |
| 2026-03-31 | 22,265,636 | -4.5% | 8,061,200 | 2.76 |
| 2026-03-13 | 23,327,094 | -7.0% | 7,366,296 | 3.17 |
| 2026-02-27 | 25,086,679 | +20.8% | 10,013,422 | 2.51 |
| 2026-02-13 | 20,767,056 | +6.2% | 9,114,561 | 2.28 |
| 2026-01-30 | 19,562,840 | -8.3% | 10,368,157 | 1.89 |
| 2026-01-15 | 21,326,879 | +4.4% | 8,769,335 | 2.43 |
| 2025-12-31 | 20,427,016 | -14.8% | 7,546,343 | 2.71 |
| 2025-12-15 | 23,972,906 | +0.3% | 8,487,235 | 2.82 |
| 2025-11-28 | 23,910,602 | +18.8% | 11,296,103 | 2.12 |
| 2025-11-14 | 20,122,322 | +3.0% | 7,257,724 | 2.77 |
| 2025-10-31 | 19,529,775 | -5.3% | 8,093,944 | 2.41 |
| 2025-10-15 | 20,626,892 | +13.5% | 8,904,507 | 2.32 |
| 2025-09-30 | 18,178,743 | -17.6% | 9,817,592 | 1.85 |
| 2025-09-15 | 22,053,691 | +17.1% | 7,281,068 | 3.03 |
| 2025-08-29 | 18,836,072 | +1.7% | 8,066,488 | 2.34 |
| 2025-08-15 | 18,516,906 | +8.0% | 8,570,372 | 2.16 |
| 2025-07-31 | 17,142,363 | -6.2% | 9,764,890 | 1.76 |
| 2025-07-15 | 18,272,250 | +15.5% | 7,044,415 | 2.59 |
| 2025-06-30 | 15,824,423 | -3.1% | 9,466,482 | 1.67 |
| 2025-06-13 | 16,330,615 | -15.0% | 6,434,190 | 2.54 |
| 2025-05-30 | 19,221,151 | -15.7% | 8,712,835 | 2.21 |
| 2025-05-15 | 22,801,009 | +15.9% | 7,920,439 | 2.88 |
| 2025-04-30 | 19,677,594 | -6.4% | 7,910,397 | 2.49 |
| 2025-04-15 | 21,018,445 | +9.8% | 14,335,774 | 1.47 |
| 2025-03-31 | 19,147,099 | -23.0% | 8,382,673 | 2.28 |
| 2025-03-14 | 24,870,261 | +7.7% | 9,459,481 | 2.63 |
| 2025-02-28 | 23,102,773 | +25.9% | 10,191,152 | 2.27 |
| 2025-02-14 | 18,352,866 | -2.2% | 7,825,742 | 2.35 |
| 2025-01-31 | 18,762,304 | +9.1% | 10,734,241 | 1.75 |
| 2025-01-15 | 17,202,144 | +4.5% | 8,305,936 | 2.07 |
| 2024-12-31 | 16,457,492 | -6.3% | 8,167,374 | 2.02 |
| 2024-12-13 | 17,572,993 | -5.2% | 8,799,853 | 2.00 |
| 2024-11-29 | 18,540,719 | +6.1% | 7,887,128 | 2.35 |
| 2024-11-15 | 17,476,968 | -3.5% | 7,487,144 | 2.33 |
| 2024-10-31 | 18,107,294 | -3.0% | 6,014,568 | 3.01 |
Daily short volume
FINRA Reg SHO, the last 30 sessions. JSONAs of 28 October 2026, the short share of JNJ volume is 29.8%, up 5.8 points over the last five sessions. Over the last 30 readings it ranged from 23.8% (16 October 2026) to 67.4% (18 September 2026). The latest reading is 12.0 points below the 30-session average of 41.7%, on 2.5M shares reported.
| Date | Short volume | Total volume | Short share | Exempt |
|---|---|---|---|---|
| 2026-10-28 | 741K | 2.5M | 29.8% | 812 |
| 2026-10-27 | 817K | 1.9M | 43.6% | 3,230 |
| 2026-10-26 | 682K | 2.0M | 34.2% | 1,959 |
| 2026-10-23 | 562K | 1.7M | 34.0% | 1,095 |
| 2026-10-22 | 1.0M | 2.9M | 35.0% | 1,219 |
| 2026-10-21 | 468K | 2.0M | 24.0% | 1,330 |
| 2026-10-20 | 1.0M | 3.2M | 32.0% | 6,303 |
| 2026-10-19 | 1.0M | 2.5M | 41.7% | 1,037 |
| 2026-10-16 | 537K | 2.3M | 23.8% | 442 |
| 2026-10-15 | 1.1M | 3.9M | 27.6% | 656 |
| 2026-10-14 | 1.2M | 3.6M | 31.9% | 1,135 |
| 2026-10-13 | 3.2M | 6.6M | 48.0% | 4,657 |
| 2026-10-12 | 845K | 1.9M | 43.9% | 1,114 |
| 2026-10-09 | 659K | 2.1M | 31.1% | 6,247 |
| 2026-10-08 | 697K | 2.1M | 33.2% | 2,740 |
| 2026-10-07 | 605K | 2.0M | 30.6% | 2,675 |
| 2026-10-06 | 650K | 1.9M | 34.2% | 648 |
| 2026-10-05 | 1.1M | 2.7M | 40.3% | 1,507 |
| 2026-10-02 | 1.6M | 3.2M | 48.7% | 713 |
| 2026-10-01 | 1.1M | 3.0M | 36.4% | 355 |
| 2026-09-30 | 947K | 1.7M | 55.1% | 8,054 |
| 2026-09-29 | 825K | 2.0M | 40.8% | 7,958 |
| 2026-09-28 | 1.0M | 1.8M | 55.2% | 3,985 |
| 2026-09-25 | 959K | 1.6M | 60.2% | 475 |
| 2026-09-24 | 1.0M | 2.1M | 48.4% | 694 |
| 2026-09-23 | 1.5M | 2.6M | 58.7% | 4,825 |
| 2026-09-22 | 1.2M | 2.0M | 59.3% | 2,212 |
| 2026-09-21 | 755K | 1.5M | 49.3% | 1,659 |
| 2026-09-18 | 1.3M | 2.0M | 67.4% | 991 |
| 2026-09-17 | 1.2M | 2.2M | 53.6% | 723 |
Fails to deliver
SEC, the last 30 settlement dates with a fail. JSONAs of 30 September 2026, the fails-to-deliver balance in JNJ is 129 shares, down 4,324 shares over the last settlement date. Over the last 30 readings it ranged from 2 shares (3 August 2026) to 220,507 shares (6 August 2026). The latest reading sits at the bottom of that range.
| Settlement | Shares failed | Price | Value |
|---|---|---|---|
| 2026-09-30 | 129 | $267.57 | $35K |
| 2026-09-29 | 4,453 | $271.95 | $1.2M |
| 2026-09-28 | 196 | $271.22 | $53K |
| 2026-09-25 | 889 | $270.68 | $241K |
| 2026-09-24 | 7,954 | $269.17 | $2.1M |
| 2026-09-23 | 6,029 | $269.19 | $1.6M |
| 2026-09-22 | 99 | $269.47 | $27K |
| 2026-09-21 | 89,357 | $269.99 | $24.1M |
| 2026-09-17 | 61 | $267.28 | $16K |
| 2026-09-08 | 991 | $275.23 | $273K |
| 2026-09-04 | 87 | $278.43 | $24K |
| 2026-09-03 | 3,068 | $275.21 | $844K |
| 2026-09-01 | 20 | $265.85 | $5K |
| 2026-08-25 | 500 | $273.04 | $137K |
| 2026-08-24 | 1,175 | $270.24 | $318K |
| 2026-08-19 | 290 | $271.11 | $79K |
| 2026-08-18 | 6 | $262.37 | $2K |
| 2026-08-17 | 74,693 | $260.35 | $19.4M |
| 2026-08-11 | 381 | $261.81 | $100K |
| 2026-08-07 | 576 | $256.98 | $148K |
| 2026-08-06 | 220,507 | $257.59 | $56.8M |
| 2026-08-03 | 2 | $256.35 | $513 |
| 2026-07-28 | 45,768 | $265.95 | $12.2M |
| 2026-07-22 | 160,367 | $250.61 | $40.2M |
| 2026-07-20 | 14,539 | $253.04 | $3.7M |
| 2026-07-17 | 82,398 | $249.97 | $20.6M |
| 2026-07-16 | 20 | $247.02 | $5K |
| 2026-07-13 | 3,989 | $256.98 | $1.0M |
| 2026-07-10 | 592 | $259.10 | $153K |
| 2026-07-07 | 64,268 | $259.33 | $16.7M |
Insider trades
SEC Form 4, newest first. JSONInsiders at JNJ reported 9 open-market sells worth $62.0M in the last 90 days and no open-market buys. Latest filing: Schmid Timothy (EVP, WW Chair, MedTech) on 2026-09-02.
| Date | Insider | Title | Type | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|---|
| 2026-09-02 | Schmid Timothy | EVP, WW Chair, MedTech | Sell | 23K | $274.74 | $6.2M | 25K |
| 2026-09-02 | Schmid Timothy | EVP, WW Chair, MedTech | Exercise or conversion | 23K | $151.41 | $3.4M | 48K |
| 2026-09-02 | Schmid Timothy | EVP, WW Chair, MedTech | Sell | 11K | $274.74 | $3.0M | 25K |
| 2026-09-02 | Schmid Timothy | EVP, WW Chair, MedTech | Exercise or conversion | 11K | $131.94 | $1.5M | 37K |
| 2026-08-17 | Taubert Jennifer L | EVP, WWC. Innovative Medicine | Sell | 15K | $263.36 | $4.0M | 194K |
| 2026-08-17 | Taubert Jennifer L | EVP, WWC. Innovative Medicine | Exercise or conversion | 15K | $115.67 | $1.7M | 209K |
| 2026-08-13 | Duato Joaquin | CEO and Chairman of the Board | Sell | 102K | $261.00 | $26.7M | 276K |
| 2026-08-13 | Duato Joaquin | CEO and Chairman of the Board | Sell | 21K | $262.00 | $5.5M | 378K |
| 2026-08-13 | Duato Joaquin | CEO and Chairman of the Board | Exercise or conversion | 123K | $115.67 | $14.3M | 399K |
| 2026-08-06 | Forminard Elizabeth | EVP, Chief Legal Officer | Sell | 7K | $255.93 | $1.7M | 17K |
| 2026-08-06 | Forminard Elizabeth | EVP, Chief Legal Officer | Sell | 9K | $257.75 | $2.4M | 24K |
| 2026-08-06 | Forminard Elizabeth | EVP, Chief Legal Officer | Exercise or conversion | 9K | $131.94 | $1.2M | 33K |
| 2026-08-05 | Duato Joaquin | CEO and Chairman of the Board | Sell | 7K | $258.74 | $1.7M | 276K |
| 2026-08-05 | Duato Joaquin | CEO and Chairman of the Board | Sell | 42K | $258.06 | $10.8M | 282K |
| 2026-07-20 | Broadhurst Vanessa | EVP, Global Corp Affairs | Sell | 23K | $251.27 | $5.8M | 23K |
| 2026-07-20 | Broadhurst Vanessa | EVP, Global Corp Affairs | Exercise or conversion | 12K | $131.94 | $1.6M | 46K |
| 2026-07-20 | Broadhurst Vanessa | EVP, Global Corp Affairs | Exercise or conversion | 11K | $129.51 | $1.4M | 34K |
| 2026-06-11 | Wengel Kathryn E | EVP, Chief TO and Risk Officer | Exercise or conversion | 10K | $115.67 | $1.2M | 124K |
| 2026-06-11 | Wengel Kathryn E | EVP, Chief TO and Risk Officer | Sell | 10K | $241.15 | $2.4M | 114K |
| 2026-05-01 | REED JOHN C | EVP, Innovative Medicine, R&D | Tax withholding | 11K | $229.85 | $2.5M | 25K |
| 2026-05-01 | REED JOHN C | EVP, Innovative Medicine, R&D | Exercise or conversion | 25K | $0.00 | $0 | 36K |
| 2026-02-27 | Decker Robert J | VP Corporate Controller | Sell | 4K | $247.87 | $1.0M | 24K |
| 2026-02-27 | Decker Robert J | VP Corporate Controller | Exercise or conversion | 4K | $115.67 | $471K | 28K |
| 2026-02-20 | Schmid Timothy | EVP, WW Chair, MedTech | Sell | 1K | $245.66 | $325K | 25K |
| 2026-02-18 | Schmid Timothy | EVP, WW Chair, MedTech | Sell | 9K | $244.53 | $2.2M | 27K |
| 2026-02-18 | Schmid Timothy | EVP, WW Chair, MedTech | Exercise or conversion | 9K | $129.51 | $1.2M | 36K |
| 2026-02-18 | Schmid Timothy | EVP, WW Chair, MedTech | Sell | 14K | $244.20 | $3.3M | 27K |
| 2026-02-18 | Schmid Timothy | EVP, WW Chair, MedTech | Exercise or conversion | 14K | $115.67 | $1.6M | 40K |
| 2026-02-17 | Swanson James D. | EVP, CIO | Sell | 21K | $242.70 | $5.0M | 26K |
| 2026-02-17 | Swanson James D. | EVP, CIO | Exercise or conversion | 21K | $164.62 | $3.4M | 46K |
| 2026-02-17 | Wolk Joseph J | Exec VP, CFO | Sell | 25K | $242.68 | $6.1M | 14K |
| 2026-02-17 | Wolk Joseph J | Exec VP, CFO | Sell | 33K | $242.75 | $8.1M | 39K |
| 2026-02-17 | Wolk Joseph J | Exec VP, CFO | Exercise or conversion | 33K | $131.94 | $4.4M | 72K |
| 2026-02-17 | Wolk Joseph J | Exec VP, CFO | Sell | 12K | $242.87 | $2.9M | 39K |
| 2026-02-17 | Wolk Joseph J | Exec VP, CFO | Exercise or conversion | 12K | $129.51 | $1.6M | 51K |
| 2026-02-17 | Wolk Joseph J | Exec VP, CFO | Sell | 19K | $242.99 | $4.7M | 39K |
| 2026-02-17 | Wolk Joseph J | Exec VP, CFO | Exercise or conversion | 19K | $115.67 | $2.2M | 58K |
| 2026-02-17 | REED JOHN C | EVP, Innovative Medicine, R&D | Sell | 2K | $243.00 | $555K | 11K |
| 2026-02-17 | REED JOHN C | EVP, Innovative Medicine, R&D | Sell | 30K | $243.00 | $7.3M | 13K |
| 2026-02-17 | REED JOHN C | EVP, Innovative Medicine, R&D | Exercise or conversion | 30K | $156.15 | $4.7M | 43K |
| 2026-02-17 | REED JOHN C | EVP, Innovative Medicine, R&D | Sell | 22K | $243.00 | $5.3M | 13K |
| 2026-02-17 | REED JOHN C | EVP, Innovative Medicine, R&D | Exercise or conversion | 22K | $157.92 | $3.4M | 35K |
| 2026-02-17 | Broadhurst Vanessa | EVP, Global Corp Affairs | Sell | 6K | $243.39 | $1.5M | 23K |
| 2026-02-15 | Swanson James D. | EVP, CIO | Tax withholding | 309 | $243.45 | $75K | 26K |
| 2026-02-15 | Swanson James D. | EVP, CIO | Exercise or conversion | 709 | $0.00 | $0 | 26K |
| 2026-02-15 | Swanson James D. | EVP, CIO | Tax withholding | 214 | $243.45 | $52K | 25K |
| 2026-02-15 | Swanson James D. | EVP, CIO | Exercise or conversion | 492 | $0.00 | $0 | 26K |
| 2026-02-15 | Wengel Kathryn E | EVP, Chief TO and Risk Officer | Tax withholding | 325 | $243.45 | $79K | 114K |
| 2026-02-15 | Wengel Kathryn E | EVP, Chief TO and Risk Officer | Exercise or conversion | 635 | $0.00 | $0 | 115K |
| 2026-02-15 | Wengel Kathryn E | EVP, Chief TO and Risk Officer | Tax withholding | 310 | $243.45 | $75K | 114K |
| 2026-02-15 | Wengel Kathryn E | EVP, Chief TO and Risk Officer | Exercise or conversion | 606 | $0.00 | $0 | 114K |
| 2026-02-15 | Mulholland Kristen | EVP, Chief HR Officer | Tax withholding | 251 | $243.45 | $61K | 20K |
| 2026-02-15 | Mulholland Kristen | EVP, Chief HR Officer | Exercise or conversion | 575 | $0.00 | $0 | 20K |
| 2026-02-15 | Mulholland Kristen | EVP, Chief HR Officer | Tax withholding | 172 | $243.45 | $42K | 20K |
| 2026-02-15 | Mulholland Kristen | EVP, Chief HR Officer | Exercise or conversion | 419 | $0.00 | $0 | 20K |
| 2026-02-15 | Wolk Joseph J | Exec VP, CFO | Tax withholding | 817 | $243.45 | $199K | 39K |
| 2026-02-15 | Wolk Joseph J | Exec VP, CFO | Exercise or conversion | 2K | $0.00 | $0 | 40K |
| 2026-02-15 | Wolk Joseph J | Exec VP, CFO | Tax withholding | 858 | $243.45 | $209K | 38K |
| 2026-02-15 | Wolk Joseph J | Exec VP, CFO | Exercise or conversion | 2K | $0.00 | $0 | 39K |
| 2026-02-15 | REED JOHN C | EVP, Innovative Medicine, R&D | Tax withholding | 528 | $243.45 | $129K | 13K |
| 2026-02-15 | REED JOHN C | EVP, Innovative Medicine, R&D | Exercise or conversion | 2K | $0.00 | $0 | 13K |
| 2026-02-15 | REED JOHN C | EVP, Innovative Medicine, R&D | Tax withholding | 385 | $243.45 | $94K | 12K |
| 2026-02-15 | REED JOHN C | EVP, Innovative Medicine, R&D | Exercise or conversion | 1K | $0.00 | $0 | 12K |
| 2026-02-15 | Taubert Jennifer L | EVP, WWC. Innovative Medicine | Tax withholding | 945 | $243.45 | $230K | 194K |
| 2026-02-15 | Taubert Jennifer L | EVP, WWC. Innovative Medicine | Exercise or conversion | 2K | $0.00 | $0 | 195K |
| 2026-02-15 | Taubert Jennifer L | EVP, WWC. Innovative Medicine | Tax withholding | 816 | $243.45 | $199K | 194K |
| 2026-02-15 | Taubert Jennifer L | EVP, WWC. Innovative Medicine | Exercise or conversion | 2K | $0.00 | $0 | 194K |
| 2026-02-15 | Schmid Timothy | EVP, WW Chair, MedTech | Tax withholding | 448 | $243.45 | $109K | 27K |
| 2026-02-15 | Schmid Timothy | EVP, WW Chair, MedTech | Exercise or conversion | 1K | $0.00 | $0 | 27K |
| 2026-02-15 | Schmid Timothy | EVP, WW Chair, MedTech | Tax withholding | 15 | $243.45 | $4K | 26K |
| 2026-02-15 | Schmid Timothy | EVP, WW Chair, MedTech | Exercise or conversion | 1K | $0.00 | $0 | 26K |
| 2026-02-15 | Forminard Elizabeth | EVP, Chief Legal Officer | Tax withholding | 544 | $243.45 | $132K | 24K |
| 2026-02-15 | Forminard Elizabeth | EVP, Chief Legal Officer | Exercise or conversion | 1K | $0.00 | $0 | 24K |
| 2026-02-15 | Forminard Elizabeth | EVP, Chief Legal Officer | Tax withholding | 492 | $243.45 | $120K | 23K |
| 2026-02-15 | Forminard Elizabeth | EVP, Chief Legal Officer | Exercise or conversion | 961 | $0.00 | $0 | 24K |
| 2026-02-15 | Duato Joaquin | CEO and Chairman of the Board | Tax withholding | 2K | $243.45 | $477K | 324K |
| 2026-02-15 | Duato Joaquin | CEO and Chairman of the Board | Exercise or conversion | 5K | $0.00 | $0 | 326K |
| 2026-02-15 | Duato Joaquin | CEO and Chairman of the Board | Tax withholding | 2K | $243.45 | $390K | 322K |
| 2026-02-15 | Duato Joaquin | CEO and Chairman of the Board | Exercise or conversion | 4K | $0.00 | $0 | 324K |
| 2026-02-15 | Decker Robert J | VP Corporate Controller | Tax withholding | 95 | $243.45 | $23K | 24K |
| 2026-02-15 | Decker Robert J | VP Corporate Controller | Exercise or conversion | 344 | $0.00 | $0 | 24K |
| 2026-02-15 | Decker Robert J | VP Corporate Controller | Tax withholding | 94 | $243.45 | $23K | 23K |
| 2026-02-15 | Decker Robert J | VP Corporate Controller | Exercise or conversion | 339 | $0.00 | $0 | 24K |
| 2026-02-15 | Broadhurst Vanessa | EVP, Global Corp Affairs | Tax withholding | 270 | $243.45 | $66K | 29K |
| 2026-02-15 | Broadhurst Vanessa | EVP, Global Corp Affairs | Exercise or conversion | 526 | $0.00 | $0 | 29K |
| 2026-02-15 | Broadhurst Vanessa | EVP, Global Corp Affairs | Tax withholding | 252 | $243.45 | $61K | 29K |
| 2026-02-15 | Broadhurst Vanessa | EVP, Global Corp Affairs | Exercise or conversion | 492 | $0.00 | $0 | 29K |
| 2026-02-13 | Swanson James D. | EVP, CIO | Sell | 22K | $243.71 | $5.4M | 25K |
| 2026-02-13 | Swanson James D. | EVP, CIO | Exercise or conversion | 22K | $162.75 | $3.6M | 47K |
| 2026-02-13 | Swanson James D. | EVP, CIO | Sell | 19K | $243.76 | $4.7M | 25K |
| 2026-02-13 | Swanson James D. | EVP, CIO | Exercise or conversion | 19K | $165.89 | $3.2M | 44K |
| 2026-02-13 | Swanson James D. | EVP, CIO | Tax withholding | 4K | $244.55 | $867K | 25K |
| 2026-02-13 | Swanson James D. | EVP, CIO | Exercise or conversion | 9K | $0.00 | $0 | 29K |
| 2026-02-13 | Swanson James D. | EVP, CIO | Tax withholding | 143 | $244.55 | $35K | 19K |
| 2026-02-13 | Swanson James D. | EVP, CIO | Exercise or conversion | 447 | $0.00 | $0 | 19K |
| 2026-02-13 | Wengel Kathryn E | EVP, Chief TO and Risk Officer | Tax withholding | 6K | $244.55 | $1.6M | 114K |
| 2026-02-13 | Wengel Kathryn E | EVP, Chief TO and Risk Officer | Exercise or conversion | 14K | $0.00 | $0 | 120K |
| 2026-02-13 | Wengel Kathryn E | EVP, Chief TO and Risk Officer | Tax withholding | 217 | $244.55 | $53K | 106K |
| 2026-02-13 | Wengel Kathryn E | EVP, Chief TO and Risk Officer | Exercise or conversion | 651 | $0.00 | $0 | 107K |
| 2026-02-13 | Mulholland Kristen | EVP, Chief HR Officer | Tax withholding | 1K | $244.55 | $251K | 19K |
Form 4 filings are due within two business days of the trade. Insiders sell for many reasons that say nothing about the company; open-market buys are rarer.
Planned sales (Form 144)
Newest first. JSON17 Form 144 notices on file for JNJ worth $143.7M at the prices reported; 4 in the last 90 days worth $49.5M. Latest: Schmid Timothy filed on 2026-09-02 to sell 33,597 shares ($9.2M) from 2026-09-02.
| Filed | Seller | Shares | Market value | Of outstanding | Sale from | Broker |
|---|---|---|---|---|---|---|
| 2026-09-02 | Schmid TimothyOfficer | 34K | $9.2M | 0.001% | 2026-09-02 | Fidelity Brokerage Services LLC |
| 2026-08-17 | Taubert Jennifer LOfficer | 15K | $4.0M | 0.001% | 2026-08-17 | Fidelity Brokerage Services LLC |
| 2026-08-13 | Duato JoaquinOfficer, Director | 123K | $32.2M | 0.005% | 2026-08-13 | Fidelity Brokerage Services LLC |
| 2026-08-06 | Forminard ElizabethOfficer | 16K | $4.1M | 0.001% | 2026-08-06 | Fidelity Brokerage Services LLC |
| 2026-07-20 | Broadhurst VanessaOfficer | 23K | $5.8M | 0.001% | 2026-07-20 | Fidelity Brokerage Services LLC |
| 2026-06-11 | Wengel Kathryn EOfficer | 10K | $2.4M | 0.000% | 2026-06-11 | Fidelity Brokerage Services LLC |
| 2026-02-27 | Decker Robert JOfficer | 4K | $1.0M | 0.000% | 2026-02-27 | Fidelity Brokerage Services LLC |
| 2026-02-20 | Schmid TimothyOfficer | 1K | $325K | 0.000% | 2026-02-20 | Fidelity Brokerage Services LLC |
| 2026-02-18 | Schmid TimothyOfficer | 23K | $5.5M | 0.001% | 2026-02-18 | Fidelity Brokerage Services LLC |
| 2026-02-17 | Swanson James D.Officer | 21K | $5.0M | 0.001% | 2026-02-17 | Fidelity Brokerage Services LLC |
| 2026-02-17 | Wolk Joseph JOfficer | 90K | $21.8M | 0.004% | 2026-02-17 | Fidelity Brokerage Services LLC |
| 2026-02-17 | REED JOHN COfficer | 54K | $13.1M | 0.002% | 2026-02-17 | Fidelity Brokerage Services LLC |
| 2026-02-17 | Broadhurst VanessaOfficer | 6K | $1.5M | 0.000% | 2026-02-17 | Fidelity Brokerage Services LLC |
| 2026-02-13 | Swanson James D.Officer | 42K | $10.1M | 0.002% | 2026-02-13 | Fidelity Brokerage Services LLC |
| 2026-02-05 | Forminard ElizabethOfficer | 6K | $1.5M | 0.000% | 2026-02-05 | Fidelity Brokerage Services LLC |
| 2026-01-26 | Joaquin DuatoCEO, Chariman | 100K | $22.0M | 0.004% | 2026-01-26 | J.P. Morgan Securities LLC |
| 2025-10-17 | REED JOHN COfficer | 22K | $4.2M | 0.001% | 2025-10-17 | Fidelity Brokerage Services LLC |
Large holders (13D and 13G)
One row per reporting person with its latest filing, newest first. JSON1 holder reports 5% or more of JNJ in its latest filing, on Schedule 13G (passive). The holder is Vanguard Capital Management at 7.5% of the class (180,631,228 shares), filed 2026-05-01 for an event on 2026-03-31.
| Filed | Form | Holder | Shares | Of class | Event |
|---|---|---|---|---|---|
| 2026-05-01 | 13G | Vanguard Capital Managementinvestment adviser | 180.6M | 7.5% | 2026-03-31 |
| 2026-03-26 | 13G/Ano. 10 | The Vanguard Groupinvestment adviser | 0 | 0.0% | 2026-03-13 |
13F holders
Tracked managers holding JNJ at their latest 13F. JSON8 of the 30 tracked managers held JNJ at their latest 13F, $5.01B in total at quarter-end prices. Fisher Asset Management is the largest at $3.38B (1.0% of its portfolio) as of 2026-06-30. Over the prior quarter 2 added shares and 6 cut.
| Fund | Quarter | Shares | Value | Of portfolio | Change in shares |
|---|---|---|---|---|---|
| Fisher Asset Management | 2026-06-30 | 13.3M | $3.38B | 1.01% | +4.0M |
| AQR Capital Management | 2026-06-30 | 2.9M | $738.5M | 0.26% | -635K |
| Citadel Advisors | 2026-06-30 | 1.5M | $381.2M | 0.04% | -430K |
| D. E. Shaw & Co. | 2026-06-30 | 687K | $174.5M | 0.08% | -77K |
| Bridgewater Associates | 2026-06-30 | 669K | $169.9M | 0.70% | -28K |
| Millennium Management | 2026-06-30 | 594K | $150.9M | 0.05% | +18K |
| Two Sigma Investments | 2026-06-30 | 35K | $8.9M | 0.01% | -18K |
| Soros Fund Management | 2026-06-30 | 34K | $8.6M | 0.11% | -827 |
Only the 30 tracked managers on the funds hub; a 13F reports long positions in US listed stock at quarter end, 45 days late, and says nothing about shorts or positions sold since.
Financials
SEC XBRL, as filed. JSONIn Q3 FY 2026 (quarter ended 2026-09-27) Johnson & Johnson reported revenue of $25.40B, up 5.9% from the same quarter a year earlier, and net income of $210.0M (0.09 diluted EPS). In FY 2025 it generated $24.53B of operating cash flow and spent $5.95B on buybacks. As of 2026-09-27, cash was $16.91B against $35.80B of debt.
- Cash
- $16.91B
- Debt
- $35.80B
- Equity
- $81.53B
- Total assets
- $197.43B
- Shares outstanding
- 2,407,310,266
Quarterly, last 8 quarters
| Quarter | Period end | Revenue | Net income | Margin | Diluted EPS |
|---|---|---|---|---|---|
| Q3 FY 2026 | 2026-09-27 | $25.40B | $210.0M | 0.8% | 0.09 |
| Q2 FY 2026 | 2026-06-28 | $25.31B | $5.53B | 21.9% | 2.27 |
| Q1 FY 2026 | 2026-03-29 | $24.06B | $5.24B | 21.8% | 2.14 |
| Q4 FY 2025derived | 2025-12-28 | $24.56B | $5.12B | 20.8% | n/a |
| Q3 FY 2025 | 2025-09-28 | $23.99B | $5.15B | 21.5% | 2.12 |
| Q2 FY 2025 | 2025-06-29 | $23.74B | $5.54B | 23.3% | 2.29 |
| Q1 FY 2025 | 2025-03-30 | $21.89B | $11.00B | 50.2% | 4.54 |
| Q3 FY 2024 | 2024-09-29 | $22.47B | $2.69B | 12.0% | 1.11 |
Fiscal years, with buybacks and dividends
| Fiscal year | Ends | Revenue | Net income | Operating cash flow | Capex | Buybacks | Dividends |
|---|---|---|---|---|---|---|---|
| FY 2025 | 2025-12-28 | $94.19B | $26.80B | $24.53B | $4.83B | $5.95B | n/a |
| FY 2024 | 2024-12-29 | $88.82B | $14.07B | $24.27B | $4.42B | $2.43B | n/a |
| FY 2023 | 2023-12-31 | $85.16B | $35.15B | $22.79B | $4.54B | $5.05B | n/a |
| FY 2023 | 2023-01-01 | $79.99B | $17.94B | $21.19B | $4.01B | $6.04B | n/a |
| FY 2022 | 2022-01-02 | $78.74B | $20.88B | $23.41B | $3.65B | $3.46B | n/a |
Quarters are the three-month figures the company reports; a fourth quarter marked derived is the fiscal year less the three reported quarters, since companies report it only inside the 10-K. Fiscal years are the annual figures. Buybacks are the cash the company paid to repurchase its common stock in the year, not the amount authorized. Balance sheet lines are as of 2026-09-27; shares outstanding as of 2026-10-15 from the cover page.
Federal contracts
The largest contract actions for Johnson & Johnson and its subsidiaries. JSON1 contract action on file for JNJ: $385K obligated in the last 90 days and $385K in the last 12 months across 1 awarding agency. The largest was $385K from the Department of Veterans Affairs on 2026-10-05 (emergency pharmacy carvykti for rmr). This covers the largest contract actions, not every award, and agencies report late.
| Action date | Agency | Amount | Type | Description |
|---|---|---|---|---|
| 2026-10-05 | Department of Veterans AffairsDepartment of Veterans Affairs | $385K | new awarddelivery order | EMERGENCY PHARMACY CARVYKTI FOR RMRUSAspending |
What this page is
Johnson & Johnson in the regulatory record
Regulators publish company data in separate files that never sit next to each other: FINRA's twice-monthly short interest, its daily short sale volume, the SEC's fails-to-deliver counts, and each insider's Form 4. A company page puts those series for one ticker on one URL, with planned sales, large holders, 13F holders and financials beside them, so the short position, the daily flow, the settlement fails and what insiders are doing can be read together.
Each section has its own history table, a one-line summary of the latest figures and its own JSON and CSV links, and says when its source last updated.
This page follows Johnson & Johnson (JNJ), SEC CIK 200406, listed on NYSE, classified by the SEC as pharmaceutical preparations. The cross-market tables live on the short interest and insider transactions hubs.
Source and updates
- Short interest
- FINRA consolidated short interestSource: FINRA.Twice a month, about eight business days after settlement. Latest 2026-10-15.JSON and CSV
- Daily short volume
- FINRA Reg SHO daily filesSource: FINRA.Every trading day, the morning after FINRA posts it. Latest 2026-10-28.JSON and CSV
- Fails to deliver
- SEC fails-to-deliver dataSource: SEC.Twice a month, a few weeks after the half month ends. Latest 2026-09-30.JSON and CSV
- Planned sales
- SEC EDGAR Form 144Source: SEC.New notices appear shortly after the SEC posts them; a notice is filed on or before the sale. Latest 2026-09-02.JSON and CSV
- Large holders
- SEC EDGAR Schedule 13D and 13GSource: SEC.New filings appear shortly after the SEC posts them. A 13D is due within five business days of crossing 5%; a 13G follows the passive schedule. Latest 2026-05-01.JSON and CSV
- 13F holders
- SEC EDGAR Form 13F-HRSource: SEC.Quarterly, filed within 45 days of quarter end; 30 tracked managers. Latest 2026-06-30.JSON and CSV
- Financials
- SEC EDGAR 10-K and 10-Q filingsSource: SEC.Weekly; values are as filed in the 10-Q and 10-K. Latest 2026-09-27.JSON and CSV
- Federal contracts
- USAspending.govSource: USAspending.gov.The largest contract actions each day, as agencies report them (up to 90 days late). Latest 2026-10-05.JSON and CSV
- Earnings dates
- SEC EDGAR 8-K filings (Item 2.02)Source: SEC.Twice a day. Reported dates come from the company's 8-K filings; the next date is marked as an estimate until the 8-K arrives. Latest 2026-10-13.JSON and CSV
- Insider trades
- SEC EDGAR Form 4Source: SEC.New filings appear shortly after the SEC posts them; they're due two business days after the trade. Latest 2026-09-02.JSON and CSV
- Company record
- EDGAR filing index for CIK 200406Ticker, name and exchange from the SEC's company list, refreshed weekly.
- Rate limits
- 10 requests a minute without a key, 30 with a free key from a free account.
How to read it
- Read the position against the flow: rising short interest with a high daily short share is new shorting; rising short interest with a normal short share is old shorts holding on.
- Insider buys next to a large short position are rare and stand out; insider sells next to one are common and mean little.
- Fails to deliver matter relative to the float, not in absolute shares; a million failed shares in a mega cap is noise.
Analysis of what the data shows, not advice. XOOMAR does not recommend buying, selling or holding anything.
Other companies the SEC classifies as pharmaceutical preparations
Other company pages
Datasets
Frequently Asked Questions
How much of JNJ is sold short?
16,766,729 shares were held short at the 2026-10-15 settlement, 2.0 days of average volume. FINRA publishes the next count about eight business days after the 15th and the last business day of the month.
What is JNJ's daily short volume?
On 2026-10-28, 741,237 of the 2,491,302 JNJ shares reported to FINRA were sold short, 29.8% of the day's reported volume. Short volume is a flow for one day, not a position.
Does JNJ have fails to deliver?
The SEC's latest file shows 129 JNJ shares failed to deliver at settlement 2026-09-30. Fails are reported per settlement date and published twice a month with a lag.
Are JNJ insiders buying or selling?
Insiders at JNJ reported 9 open-market sells worth $62.0M in the last 90 days and no open-market buys. Latest filing: Schmid Timothy (EVP, WW Chair, MedTech) on 2026-09-02.
Have JNJ insiders filed to sell?
17 Form 144 notices on file for JNJ worth $143.7M at the prices reported; 4 in the last 90 days worth $49.5M. Latest: Schmid Timothy filed on 2026-09-02 to sell 33,597 shares ($9.2M) from 2026-09-02.
Who owns 5% or more of JNJ?
1 holder reports 5% or more of JNJ in its latest filing, on Schedule 13G (passive). The holder is Vanguard Capital Management at 7.5% of the class (180,631,228 shares), filed 2026-05-01 for an event on 2026-03-31.
What did JNJ report last quarter?
In Q3 FY 2026 (quarter ended 2026-09-27) Johnson & Johnson reported revenue of $25.40B, up 5.9% from the same quarter a year earlier, and net income of $210.0M (0.09 diluted EPS). In FY 2025 it generated $24.53B of operating cash flow and spent $5.95B on buybacks. As of 2026-09-27, cash was $16.91B against $35.80B of debt.
Which tracked 13F managers own JNJ?
8 of the 30 tracked 13F managers held JNJ shares at their latest filing, $5.01B in all. The largest: Ken Fisher's Fisher Asset Management (13.3M shares, $3.38B), Cliff Asness's AQR Capital Management (2.9M shares, $738.5M), Ken Griffin's Citadel Advisors (1.5M shares, $381.2M), D. E. Shaw & Co. (687K shares, $174.5M), Ray Dalio's Bridgewater Associates (669K shares, $169.9M), Izzy Englander's Millennium Management (594K shares, $150.9M). The table above lists all 8.
How much federal contract money did JNJ receive?
$385K was obligated to Johnson & Johnson and its subsidiaries in the last 90 days and $385K in the last 12 months, counting the largest contract actions on USAspending, not every award. Obligations are not revenue; they are spent over each contract's life.
Data on this page is provided for informational purposes only and is not financial advice. See our editorial policy.